| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-99 |
Sentence |
denotes |
Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. |
| TextSentencer_T2 |
100-311 |
Sentence |
denotes |
Severe coronavirus disease 2019 (COVID-19) is commonly complicated with coagulopathy, the difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 has not been analyzed. |
| TextSentencer_T3 |
312-533 |
Sentence |
denotes |
Coagulation results and clinical features of consecutive patients with severe pneumonia induced by SARS-CoV2 (COVID group) and non-SARS-CoV2 (non-COVID group) in Tongji hospital were retrospectively analyzed and compared. |
| TextSentencer_T4 |
534-630 |
Sentence |
denotes |
Whether patients with elevated D-dimer could benefit from anticoagulant treatment was evaluated. |
| TextSentencer_T5 |
631-712 |
Sentence |
denotes |
There were 449 COVID patients and 104 non-COVID patients enrolled into the study. |
| TextSentencer_T6 |
713-1013 |
Sentence |
denotes |
The 28-day mortality in COVID group was approximately twofold of mortality in non-COVID group (29.8% vs. 15.4%, P = 0.003), COVID group were older (65.1 ± 12.0 vs. 58.4 ± 18.0, years, P < 0.001) and with higher platelet count (215 ± 100 vs. 188 ± 98, ×109/L, P = 0.015), comparing to non-COVID group. |
| TextSentencer_T7 |
1014-1146 |
Sentence |
denotes |
The 28-day mortality of heparin users were lower than nonusers In COVID group with D-dimer > 3.0 μg/mL (32.8% vs. 52.4%, P = 0.017). |
| TextSentencer_T8 |
1147-1354 |
Sentence |
denotes |
Patients with severe pneumonia induced by SARS-CoV2 had higher platelet count than those induced by non-SARS-CoV2, and only the former with markedly elevated D-dimer may benefit from anticoagulant treatment. |
